文献速递鼻科

慢性鼻窦炎伴鼻息肉手术与生物治疗的西班牙NHS经济学分析

Economic analysis of surgery and biological therapy for chronic rhinosinusitis with nasal polyps.
PubMed 文献 · Rhinology · 2026-01-01

本研究从西班牙国家卫生系统(NHS)视角,对严重慢性鼻窦炎伴鼻息肉(CRSwNP)的内镜鼻窦手术(ESS)与生物治疗进行经济评价,数据来自三级医院并做10年预测。纳入89例患者(ESS 63例、生物制剂26例),2年时两者SNOT-22改善相似(-31.8 vs -31.0),但ESS费用远低于生物制剂(EUR 5,302.78 vs EUR 27,198.23),生物制剂2年ICUR为EUR 1.2 million/QALY,高于可接受阈值。10年时生物制剂获得2.75 QALYs、增量成本EUR 108,917.62(ICUR EUR 39,592/QALY),敏感性分析显示生物制剂通常仍高于常用支付意愿阈值,仅大幅降价(最高40%)可使ICUR接近可接受上限。结论认为ESS短期成本更低且更高效,生物制剂长期QALY增益更高但成本显著增加,在西班牙NHS内仅 favorable pricing 假设下可能接近成本效果,应保留给有禁忌或ESS后持续疾病患者。

要点

  • 2年时ESS与生物制剂SNOT-22改善相似,但ESS费用远低于生物制剂。
  • 生物制剂2年ICUR为EUR 1.2 million/QALY,高于可接受阈值。
  • 10年生物制剂ICUR为EUR 39,592/QALY,仍多高于常用支付意愿阈值。

核心结论

  • ESS短期成本更低且更高效,生物制剂长期QALY增益更高但成本显著增加。
  • 在西班牙NHS内,生物制剂仅在大幅降价等有利定价假设下可能接近成本效果,应保留给有禁忌或ESS后持续疾病患者。

研究设计与样本

  • 从西班牙NHS视角对严重CRSwNP进行经济评价,遵循西班牙NHS指南。
  • 数据来自三级医院,含10年预测,纳入89例患者(ESS 63例、生物制剂26例)。
  • 效果以SNOT-22改善衡量,成本效用分析采用QALYs,ESS用micro-costing,生物制剂用年药费,并做敏感性分析。

主要发现

  • 2年后两种策略SNOT-22改善相似(ESS -31.8,生物制剂 -31.0)。
  • ESS费用为EUR 5,302.78,远低于生物制剂的EUR 27,198.23。
  • 生物制剂2年ICUR为EUR 1.2 million/QALY,高于可接受阈值。
  • 10年时生物制剂获得2.75 QALYs,增量成本EUR 108,917.62,ICUR EUR 39,592/QALY。
  • 敏感性分析显示生物制剂通常仍高于常用支付意愿阈值,降价最高40%可使ICUR接近可接受上限。

关键数值与推荐

  • 2年SNOT-22改善:ESS -31.8,生物制剂 -31.0。
  • 2年费用:ESS EUR 5,302.78,生物制剂 EUR 27,198.23。
  • 2年ICUR:生物制剂 EUR 1.2 million/QALY。
  • 10年:生物制剂2.75 QALYs,增量成本EUR 108,917.62,ICUR EUR 39,592/QALY。
  • 降价最高40%可使生物制剂ICUR接近可接受上限。

临床怎么用

  • 在西班牙NHS背景下,ESS应作为短期更经济的策略。
  • 生物制剂应保留给有禁忌或ESS后持续疾病的患者。
  • 生物制剂接近成本效果需依赖大幅降价等有利定价假设。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) imposes major health and economic burdens. Endoscopic sinus surgery (ESS) and biologic therapy are treatment options. This study compares their effectiveness and cost-efficiency from the Spanish National Health System (NHS) perspective. METHODOLOGY: An economic evaluation was conducted in severe CRSwNP, following Spanish-NHS guidelines. Data came from a tertiary-hospital with 10-year projections. Effectiveness was measured as reduction in the Sinonasal Outcome Test-22 (SNOT-22). Cost-utility analysis used quality-adjusted life years (QALYs). Micro-costing was applied for ESS, while annual drug costs were considered for biologics. Sensitivity analyses tested robustness. RESULTS: 89 patients were included (63 ESS, 26 biologics). After 2-years, both strategies achieved similar SNOT-22 improvements (-31.8 ESS, -31.0 biologics). Costs were far lower for ESS (EUR 5,302.78) than biologics (EUR 27,198.23), making biologics less efficient despite comparable benefit. The 2-year incremental cost-utility ratio (ICUR) for biologics was EUR 1.2 million/QALY, above accepted thresholds. At 10-years, biologics yielded 2.75 QALYs at an incremental cost of EUR 108,917.62 (ICUR EUR 39,592/QALY). Sensitivity ana-lyses showed that biologics generally remained above commonly accepted willingness-to-pay thresholds, although substantial price reductions (up to 40%) allowed ICURs to approach the upper limit of acceptability. CONCLUSIONS: Both treatments provide meaningful improvement. ESS remained the less costly strategy and was more efficient over the short term, whereas long-term projections showed higher QALY gains with biologics at substantially greater cost. Within Spanish- NHS, biologics may approach cost-effectiveness only under favorable pricing assumptions and should be reserved for patients with contraindications or persistent disease after ESS.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Maza-Solano J, Garcia Mochon L, Martin-Martin J, et al. Economic analysis of surgery and biological therapy for chronic rhinosinusitis with nasal polyps. Rhinology. 2026. PMID: 42165784. doi:10.4193/Rhin25.529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。